Using Computer Tasks to Predict Response to Antidepressants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In England over 800,000 patients each year are either newly diagnosed with depression or present with a new episode of depression in primary care. The majority of patients do not respond to the first drug prescribed and have to try several different antidepressants before an effective treatment is found. Antidepressants have a slow clinical onset of action, taking 4 to 6 weeks before changes in mood become apparent. No test exists to guide General Practitioners (GPs) as to whether their patient is responding to the prescribed successive treatments. This often results in delays of many months before patients return to good mental health. The GP-ETB is a set of computer-based emotional processing tasks. It was developed and optimised to be sensitive to early changes in emotional bias that are indicative of successful antidepressant treatment. The current investigation is an exploratory study using the GP-ETB.

It will test the predictive ability of the GP-ETB with regard to later subjective drug response and nonresponse. The study will recruit depressed patients from primary care settings. There are no study drugs prescribed as part of this clinical investigation. Eligible patients will have been prescribed citalopram by their GP prior to study entry. The decision to initiate treatment with citalopram will be independent of study participation. The duration of the study is 5 months. Each patient will be required to attend 3 visits and total duration of the study for the patient will be 46 weeks. During the visits patients will be asked to complete a variety of questionnaires and GP-ETB tasks on the computer. Sensitivity and specificity data collected during this study will be used to develop a computer algorithm intended to predict response at 46 weeks, based on GP-ETB data collected 1 week after initiation of antidepressant treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predicting Response to Depression Treatment (PReDicT)

NCT02790970

Depression

COMPLETED NA

Post Marketing Study for the Evaluation of Predictix Antidepressant Clinician Software Support Tool in Prescribing Antidepressant Medication/s for the Treatment of Patients Suffering From Major Depressive Disorder

NCT04138290

Major Depressive Disorder

UNKNOWN PHASE4

The Efficacy of Automated Feedback After Internet-based Depression Screening

NCT04633096

Depression Major Depressive Disorder

COMPLETED NA

Effects of Seven Day Prucalopride Administration in Healthy Volunteers

NCT03572790

Molecular Mechanisms of Pharmacological Action Depression Depressive Disorder +4 more

COMPLETED NA

PRediction Of Treatment Response to ECT in Depression and Cognitive Side effecTs

NCT02562846

Depression

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is an exploratory, single arm, multi-centre, clinical investigation of a medical device. The study consists of a recruitment period followed within 3 days by the first study visit. After a GP has decided to prescribe citalopram for depression, GP assesses patient for suitability for study and provides a brief explanation of study to potentially suitable patient. Patient signs pre-study consent form agreeing to being contacted by researcher from the same or another GP surgery and agreeing not to take their first dose of citalopram until after their first study visit.

Recruitment and pre-screening Main study Patient Information Sheet/Informed Consent Form (PIS/ICF) will be provided. Researcher will contact patient and book the Visit 1 within 3 days from GP visit.

At Visit 1, patients will be screened and eligible patients will be enrolled in the study. Visit 1 procedures include:

* Informed Consent
* Demographics
* Review of other medication
* Brief medical history including depression history (if applicable)
* Entry criteria check and enrolment into study
* Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR)
* Montgomery-Åsberg Depression Rating Scale (MADRS)
* Beck Depression Inventory®II (BDI-II)
* GP-ETB (set of computer tasks)
* Review of Adverse Events (AEs) and Adverse Device Effects (ADEs) and device deficiencies Patients will return approximately 1 week later for Visit 2 and will complete a variety of questionnaires and assessments:
* QIDS-SR
* BDI-II
* GP-ETB
* Assessment of compliance with study prohibitions and restrictions
* Changes to antidepressant medication since last visit (e.g. increased dose, change of drug)
* Concordance with prescribed antidepressant medication, as determined through interview with patient
* Review of other medication
* Review of AEs, ADEs and device deficiencies Visit 3 will be scheduled to take place 46 weeks after the first dose of citalopram. The following questionnaires and assessments will be completed:
* QIDS-SR
* MADRS
* BDI-II
* Acceptability questionnaire(s) relating to use of GP-ETB (patient and researcher)
* Assessment of compliance with study prohibitions and restrictions
* Changes to antidepressant medication since last visit (e.g. increased dose, change of drug)
* Concordance with prescribed antidepressant medication, as determined through interview with patient
* Review of other medication
* Review of AEs, ADEs and device deficiencies At the end of the visit, patients will be considered to have completed the study.

Emotional Test Battery (GP-ETB) tasks: The GP-ETB is a series of computerised tasks during which participants must respond by button press to pictures (e.g. pictures of faces) or words presented on the screen. Some of the pictures are mildly emotional (e.g. a fearful face). Response bias for each Participant choice and reaction times are measured during the following tasks: Emotional Categorisation Task (ECAT) Number of words categorised as liked and disliked

% accuracy for each condition, Reaction time for each condition Emotional Recall Task (EREC) Total number of words recalled for each valence (positive, negative) Number of commission errors

Facial Expression Recognition Task (FERT):

* accuracy of recognition of each emotion (happiness, fear, anger, disgust, surprise, sadness, neutral)
* mis-classifications for each emotion Individual average reaction time for correct answers in each emotion Reaction time for all emotions Target sensitivity for each emotion Response bias for each emotion Questionnaires and rating scales: The questionnaires and rating scales used in the current study, except the acceptability questionnaires relating to use of GP-ETB (patient and researcher), are all validated and commonly used in experimental medicine studies.

The acceptability questionnaires relating to use of GP-ETB were created specifically for this study to obtain a data set for analysis of GP-ETB user satisfaction.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All participants

Study has a single, non-interventional arm where the General Practitioner Emotional Test Battery (GP-ETB) will be administered.

Group Type OTHER

General Practitioner Emotional Test Battery (GP-ETB)

Intervention Type DEVICE

The GP-ETB (Class I Medical Device) comprises three computer tasks. In the first task, the 'Emotional Categorisation Task' patients are given forty words that might be used to describe them and indicate whether they would 'like' or 'dislike' to be described by a particular word. In the 'Facial Expression Recognition Task' patients are asked to judge whether a briefly displayed face is expressing one of six emotions. In the final task, the 'Emotional Recall Task', the patient should recall as many words as they can from the series of words that were presented in the first task. The patients perform these tasks once before antidepressant treatment and again seven days after treatment begins.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

General Practitioner Emotional Test Battery (GP-ETB)

The GP-ETB (Class I Medical Device) comprises three computer tasks. In the first task, the 'Emotional Categorisation Task' patients are given forty words that might be used to describe them and indicate whether they would 'like' or 'dislike' to be described by a particular word. In the 'Facial Expression Recognition Task' patients are asked to judge whether a briefly displayed face is expressing one of six emotions. In the final task, the 'Emotional Recall Task', the patient should recall as many words as they can from the series of words that were presented in the first task. The patients perform these tasks once before antidepressant treatment and again seven days after treatment begins.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female and aged between 18 and 65 inclusive.
2. Diagnosed by GP with a depressive episode requiring treatment with citalopram (new or recurrent diagnosis).
3. Prescribed citalopram by GP for treatment of depression within past 3 days but has not yet started taking medication.
4. Is intending to start citalopram treatment within 2 days of Visit 1.
5. Fluent English speaker.
6. Has not consumed more than 4 units of alcohol in the 24 hours prior to Visit 1 and has not consumed any alcohol in the 8 hours prior to Visit 1.
7. Has not smoked tobacco in the 2 hours prior to completing the GP-ETB at Visit 1.
8. Has not consumed any beverages containing caffeine for 2 hours prior to completing the GPETB at Visit 1.
9. Has not consumed any psychoactive substances for 24 hours prior to Visit 1.
10. Willing and able to comply with study procedures, including treatment with citalopram and study prohibitions and restrictions.
11. Patient must have signed the informed consent form prior to the first study related procedure indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion Criteria

1. Pregnant or breastfeeding, or planning to become pregnant during study, as determined through interview with patient.
2. Currently taking antidepressant medication.
3. Has taken antidepressant medication in the past 3 months.
4. Currently taking anti-psychotic or regular sedative medication, or is likely to require these during the study.
5. Regular (at least every week) use of recreational drugs including cannabis, as determined through interview with patient.
6. History of alcohol or substance dependence within the last 12 months from Visit 1, as assessed using standard screening questions.
7. Unlikely to be able to complete GP-ETB test.
8. Requires immediate referral to secondary care mental health services.
9. Is employed by the investigator or is related to the investigator
10. Currently taking part in a drug study or another device study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No